Dataset Information

Therapeutic Effect of Calcipotriol Pickering Nanoemulsions Prepared by Exopolysaccharides Produced by Bacillus halotolerans FYS Strain on Psoriasis.

ABSTRACT:

Purpose

Many exopolysaccharides (EPS) have significant emulsifying activity. Some EPS produced by the marine bacterial strain FYS have stronger emulsifying activity in the form of nanoparticles, suggesting that they could potentially form Pickering emulsions. We prepared novel EPS/CT Pickering nanoemulsions (ECPN) with EPS as emulsifiers and assessed their ability to ameliorate the poor permeability of calcipotriol (CT) in skin affected by psoriasis vulgaris.

Methods

A strain of marine bacterium FYS was identified. Molecular weight, monosaccharide composition and microstructure of EPS were determined by gel permeation chromatography, high-performance liquid chromatography and scanning electron microscopy. EPS nanoparticles were prepared by adjusting the pH, and the emulsifying activity was studied at different pH. ECPN were prepared by ultrasound and optimized by the response surface method. The size distribution, microstructure, stability and in vitro drug release of ECPN were studied. The therapeutic effect of ECPN on psoriasis vulgaris was explored by animal experiments and characterizing histomorphology in vivo.

Results

A phylogenetic tree revealed that FYS was a Bacillus halodurans strain. EPS produced by the strain were heteropolysaccharides with a three-dimensional network composed of glucose, galactose, glucuronic acid, rhamnose, galacturonic acid and mannose (32.0:34.3:9.7:7.4:10.3:6.3). The EPS can form nanoparticles at pH = 4-6 with enhanced emulsifying ability. Transmission electron microscopy revealed that EPS nanoparticles adhered to the surface of oil droplets to stabilize the emulsions via a Pickering emulsification mechanism. The prepared ECPN have high stability with a sustained-release effect. Finally, animal experiments showed that ECPN effectively shortened the treatment course of psoriasis vulgaris.

Conclusion

EPS is highly possible to have the potential Pickering emulsification mechanism. The stability of the nanoemulsion was high. ECPN also showed potential for use in the treatment of psoriasis vulgaris. This study provides new insight into the medical applications of EPS and the treatment of psoriasis.

SUBMITTER: Wang Y

PROVIDER: S-EPMC7764976 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Therapeutic Effect of Calcipotriol Pickering Nanoemulsions Prepared by Exopolysaccharides Produced by <i>Bacillus halotolerans</i> FYS Strain on Psoriasis.

Wang Yuzhen Y Li Hong H Dong Fakun F Yan Fang F Cheng Min M Li Wanzhong W Chang Qi Q Song Tianzi T Liu Aoying A Song Bo B

International journal of nanomedicine 20201222

<h4>Purpose</h4>Many exopolysaccharides (EPS) have significant emulsifying activity. Some EPS produced by the marine bacterial strain FYS have stronger emulsifying activity in the form of nanoparticles, suggesting that they could potentially form Pickering emulsions. We prepared novel EPS/CT Pickering nanoemulsions (ECPN) with EPS as emulsifiers and assessed their ability to ameliorate the poor permeability of calcipotriol (CT) in skin affected by psoriasis vulgaris.<h4>Methods</h4>A strain of m ...[more]

PMID: 33376326

Similar Datasets

Project description:A poly(N,N'-dimethylacrylamide) (PDMAC) precursor is chain-extended via reversible addition-fragmentation chain transfer (RAFT) aqueous dispersion polymerization of diacetone acrylamide (PDAAM) to produce PDMAC77-PDAAM40 spherical nanoparticles. Post-polymerization core-crosslinking of such nanoparticles was performed at 20 °C, and the resulting covalently stabilized nanoparticles survive exposure to methanol. The linear and core-crosslinked nanoparticles were subjected to high-shear homogenization in turn in the presence of n-dodecane to form macroemulsions. Subsequent processing of these macroemulsions via high-pressure microfluidization produced nanoemulsions. When using the core crosslinked nanoparticles, the droplet diameter was strongly dependent on the copolymer concentration. This indicates that such nanoparticles remain intact under the processing conditions, leading to formation of genuine Pickering nanoemulsions with a z-average diameter of 244 ± 60 nm. In contrast, the linear nanoparticles undergo disassembly to afford molecularly dissolved diblock copolymer chains, which stabilize oil droplets of 170 ± 59 nm diameter. The long-term stability of these two types of n-dodecane-in-water nanoemulsions with respect to Ostwald ripening was examined using analytical centrifugation. When prepared at the same copolymer concentration, Pickering nanoemulsions stabilized by core-crosslinked nanoparticles proved to be significantly more stable than the nanoemulsion stabilized by the amphiphilic PDMAC77-PDAAM40 chains. Moreover, higher copolymer concentrations led to a significantly faster rate of droplet growth. This is attributed to excess copolymer facilitating the diffusion of n-dodecane through the aqueous phase. Finally, analytical centrifugation is used to assess the long-term stability of the analogous squalane-in-water nanoemulsions. These systems are much more stable than the corresponding n-dodecane-in-water nanoemulsions, regardless of whether the copolymer is adsorbed as sterically stabilized nanoparticles or surface-active chains.

Project description:BackgroundPsoriasis causes worldwide concern because of its high-prevalence, as well as its harmful, and incurable characteristics. Topical therapy is a conventional treatment for psoriasis vulgaris. Chinese medicine (CM) has been commonly used in an integrative way for psoriasis patients for many years. Some CM therapies have shown therapeutic effects for psoriasis vulgaris (PV), including relieving symptoms and improving quality of life, and may reduce the relapse rate. However, explicit evidence has not yet been obtained. The purpose of the present trial is to examine the efficacy and safety of the YXBCM01 granule, a compound Chinese herbal medicine, with a combination of topical therapy for PV patients.Methods/designUsing an add-on design, the trial is to evaluate whether the YXBCM01 granule combined topical therapy is more effective than topical therapy alone for the treatment of PV. The study design is a double-blind, parallel, randomized controlled trial comparing the YXBCM01 granule (5.5 g twice daily) to a placebo. The duration of treatment is 12 weeks. A total of 600 participants will be randomly allocated into two groups, YXBCM01 granule group and placebo group, from 11 general or dermatological hospitals in China. Topical use of calcipotriol betamethasone for the first 4 weeks and calcipotriol ointment for the remaining 8 weeks will be the same standard therapy for the two groups. Patients will be enrolled if they have a clinical diagnosis of PV, a psoriasis area severe index (PASI) of more than 10 or body surface area (BSA) of more than 10%, but PASI of less than 30 and BSA of less than 30%, are aged between 18 and 65-years-old, and provide signed informed consent. The primary outcome, relapse rate, is based on PASI assessed blindly during the treatment. Secondary outcomes include: (i) relapse time interval, (ii) time to onset, (iii) rebound rate, (iv) PASI score, (v) cumulative consumption of medicine, (vi) the dermatology quality life index (DLQI), and (vii) the medical outcomes study (MOS) item short form health survey (SF-36). Analysis will be on intention-to-treat and per-protocol subject analysis principles.DiscussionTo address the effectual remission of the YXBCM01 granule for PV, this trial may provide a novel regimen for PV patients if the granule can decrease relapse rate without more adverse effects.Trial registrationChinese Clinical Trial Registry (http://cwww.chictr.org): ChiCTR-TRC-13003233, registered 26 May 2013.